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Introduction
The colony stimulating factor granulocyte (G-CSF) is a
glycoprotein capable of promoting the survival, prolifera-
tion and differentiation of hematopoietic cells. Studies
demonstrate the cytoprotective action of G-CSF against
renal injury by ischemia/reperfusion injury in murine
models. But the literature is still controversial in relation
to the risk of worsening renal function after useG-CSF,
which motivated the study to elucidate possible interfer-
ence on the renal function of the treated animals.
Objective
Evaluate the renal function of rats after treatment with
G-CSF at different doses of the drug.
Methods
Male Wistar rats (n = 18), 200g approx. (CEUA050/2013),
divided into 3 groups (6 animals each) : control group (C)
5% glucose solution (solvent) groups treated with G-CSF
at a dose of 10 (G10) and 50 (G50) mg / kg / per 5 days.
After treatment, the rats were placed in metabolic cages
for urine collection and obtaining urine volume. Values
were obtained from creatinine, proteinuria, urea and num-
ber of circulating leukocytes. The results were expressed
as mean ± SEM. The averages ofvalues between groups
were calculated using one - way ANOVA followed by post
hoc Fisher for comparison between differentgroups.
Results
A significant increase in the number of circulating leuko-
cytes in animals treated with G- CSF (C = 9687 ± 899 /
mm3;= 14375 ± 1967/mm3 G10, and G50 = 19670 ±
1663/mm3, p < 0.05). There was not a significant increase
in urine volume after 24 hours treatment with G-CSF.
There was no significant difference between the values of
creatinine clearance, proteinuria and Urea, among groups
C, G10 and G50.
Conclusion
There was no impairment of renal function in animals
treated at doses of 10 and 50 mg / kg / per 5 days.
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